The practice allegedly purchased a compound version of triamcinolone acetonide from compounding pharmacies and billed TennCare for the higher cost, FDA-approved version of the injectable, according to a news release.
TennCare requires practices to go through prior authorization to use and bill for compounded drugs, along with documenting medical reasons for using compounded drugs and their ingredients.
The alleged billing fraud happened from Feb. 6, 2019, through Nov. 17, 2021. The practice allegedly received higher reimbursement rates from TennCare than entitled.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
